Bioorganic Chemistry p. 655 - 666 (2019)
Update date:2022-08-17
Topics:
Elmasry, Ghada F.
Aly, Enayat E.
Awadallah, Fadi M.
El-Moghazy, Samir M.
Various pyridopyridazinone derivatives were designed as Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. The pyridopyridazinone scaffold was used as an isostere of the phthalazine nucleus of the lead compound Olaparib in addition to some modifications in the tail part of the molecule. Preliminary biological evaluation indicated that most compounds possessed inhibitory potencies comparable to Olaparib in nanomolar level. The best PARP-1 inhibitory activity was observed for compound 8a with (IC50 = 36 nM) compared to Olaparib as a reference drug (IC50 = 34 nM). Molecular modeling simulation revealed that, the designed compounds docked well into PARP-1 active site and their complexes are stabilized by three key hydrogen bond interactions with both Gly863 and Ser904 as well as other favorable π-π and hydrogen-π stacking interactions with Tyr907 and Tyr896, respectively. Computational ADME study predicted that the target compounds 8a and 8e have proper pharmacokinetic and drug-likeness properties. These outcomes afford a new structural framework for the design of novel inhibitors for PARP-1.
View MoreXiamen Kaijia Imp & Exp Co., Ltd.
Contact:86-592-5101177
Address:Room406 Luhui Building No. 65 Haitian Road Huli Xiamen,China.
Chengdu Boon Stream Chemical Industry Co.,Ltd.
Contact:+86-28-83156758
Address:No.859,Dongzikou Road,Jinniu District,Chengdu,Sichuan,P.R.China
Contact:+ 86 512 52491118
Address:1 Fuyu Road, Haiyu TownChangshu, Jiangsu, China
JIANGXI AIFEIMU TECHNOLOGY CO.,LTD
Contact:+86-570-6040289
Address:FINECHEMICAL PARK,ZIBU TOWN,WANNIAN COUNTY,JIANGXI PROV.,CHINA,ZIP
Nanjing Chemipioneer Pharma&Tech Co.,Ltd
website:http://www.chemipioneer.com.cn
Contact:+86-25-52685700
Address:Room 305,A Block,Biological-Medicine Building,Business Start-up Center,Xin-ke 1st Road, High-tech development zone,Nanjing city,Jiangsu Province, China
Doi:10.1006/jcat.1998.2131
(1998)Doi:10.1016/j.ica.2018.08.051
(2019)Doi:10.1016/j.tetlet.2015.06.081
(2015)Doi:10.1093/japr/11.1.34
(1937)Doi:10.3184/174751917X15094552081134
(2017)Doi:10.1002/pssa.200306729
(2004)